Five years ago, TransMedics Group $TMDX shares were trading at a much humbler $19.00, but as of today, the stock closed at $137.07—marking a phenomenal 621.42% rise fueled by its revolutionary Organ Care System (OCS) and a growing $4.68B market cap.

This aggressive climb reflects a Compound Annual Growth Rate (CAGR) of 48.47%, meaning your money would have grown by nearly 50% each year on average as the company transformed organ transplantation logistics.

By following a dollar-cost averaging (DCA) strategy and committing $500 every month for five years (totaling $30,000), you would have leveraged the stock's volatility, buying more shares during the 2025 pullbacks and fewer during its rapid vertical ascents.

Build your portfolio, one day at a time.
Get our daily 5-year horizon picks sent to your inbox. Subscribe here.

Projecting forward at this historical pace with a monthly growth rate of approximately 3.35%, your total investment could reach $111,102 by 2031, resulting in a gain of $81,102—a 270.3% return.

While the medtech sector faces high R&D costs and a 52-week high of $156.00 shows the stock is currently consolidating, TransMedics’ expansion of its National OCS Program provides a massive operational tailwind; if you keep this steady drill running, your $500 monthly habit could turn into a life-changing windfall by 2031—but in the high-stakes world of medical innovation, will you be riding the next breakthrough or left waiting on the transplant list when the market cooling begins?